

# Paul E Greenberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11812637/publications.pdf>

Version: 2024-02-01

36  
papers

6,799  
citations

304602

22  
h-index

377752

34  
g-index

38  
all docs

38  
docs citations

38  
times ranked

8134  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication. <i>Archives of General Psychiatry</i> , 2007, 64, 543.	13.8	2,032
2	The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010). <i>Journal of Clinical Psychiatry</i> , 2015, 76, 155-162.	1.1	1,321
3	The Economic Burden of Depression in the United States. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 1465-1475.	1.1	1,104
4	Depression In The Workplace: Effects On Short-Term Disability. <i>Health Affairs</i> , 1999, 18, 163-171.	2.5	323
5	Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. <i>Depression and Anxiety</i> , 2010, 27, 78-89.	2.0	307
6	The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018). <i>Pharmacoeconomics</i> , 2021, 39, 653-665.	1.7	302
7	Workplace performance effects from chronic depression and its treatment. <i>Journal of Health Economics</i> , 1998, 17, 511-535.	1.3	167
8	Depression and Work Productivity: The Comparative Costs of Treatment Versus Nontreatment. <i>Journal of Occupational and Environmental Medicine</i> , 2001, 43, 2-9.	0.9	164
9	The economic burden of depression in the US: societal and patient perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 369-376.	0.9	135
10	Estimated Costs of Prescription Opioid Analgesic Abuse in the United States in 2001. <i>Clinical Journal of Pain</i> , 2006, 22, 667-676.	0.8	132
11	Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 24-32.	1.1	97
12	Using Healthcare Claims Data for Outcomes Research and Pharmacoeconomic Analyses. <i>Pharmacoeconomics</i> , 1999, 16, 1-8.	1.7	91
13	Economic Consequences of Not Recognizing Bipolar Disorder Patients. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 1201-1209.	1.1	86
14	Direct and indirect costs of asthma to an employer. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 264-270.	1.5	74
15	Identification of a Claims Data "Signature" and Economic Consequences for Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 717-726.	1.1	71
16	Economic Burden of Respiratory Infections in an Employed Population. <i>Chest</i> , 2002, 122, 603-611.	0.4	58
17	Direct and Indirect Costs of Rheumatoid Arthritis to an Employer. <i>Journal of Occupational and Environmental Medicine</i> , 2000, 42, 588-596.	0.9	55
18	Economic Burden of Pneumonia in an Employed Population. <i>Archives of Internal Medicine</i> , 2001, 161, 2725.	4.3	34

#	ARTICLE	IF	CITATIONS
19	Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis. PLoS ONE, 2019, 14, e0223255.	1.1	32
20	Impact of Illness and Its Treatment on Workplace Costs: Regulatory and Measurement Issues. Journal of Occupational and Environmental Medicine, 2001, 43, 56-63.	0.9	26
21	Determinants of Direct Cost Differences among US Employees with Major Depressive Disorders Using Antidepressants. Pharmacoeconomics, 2009, 27, 507-517.	1.7	25
22	Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. Current Medical Research and Opinion, 2008, 24, 2587-2595.	0.9	23
23	The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence. Expert Opinion on Pharmacotherapy, 2009, 10, 2317-2328.	0.9	21
24	Healthcare resource utilization and costs associated with postpartum depression among commercially insured households. Current Medical Research and Opinion, 2020, 36, 1707-1716.	0.9	20
25	Management of Major Depression in the Workplace. Disease Management and Health Outcomes, 2000, 7, 163-171.	0.3	19
26	Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. Journal of Medical Economics, 2009, 12, 124-135.	1.0	19
27	Medicaid spending burden among beneficiaries with treatment-resistant depression. Journal of Comparative Effectiveness Research, 2019, 8, 381-392.	0.6	18
28	Assessing the Relationship Between Compliance With Antidepressant Therapy and Employer Costs Among Employees in the United States. Journal of Occupational and Environmental Medicine, 2010, 52, 115-124.	0.9	14
29	Cost of depression: current assessment and future directions. Expert Review of Pharmacoeconomics and Outcomes Research, 2001, 1, 69-76.	0.7	11
30	Economic Burden of Commercially Insured Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United States. Journal of Clinical Psychiatry, 2022, 83, .	1.1	7
31	Does generic substitution always make sense?. Journal of Medical Economics, 2008, 11, 547-553.	1.0	5
32	Antidepressant treatment patterns and costs among US employees. Journal of Medical Economics, 2009, 12, 36-45.	1.0	3
33	Introduction to the Special Issue of Pharmacoeconomics on Major Depressive Disorders. Pharmacoeconomics, 2021, 39, 617.	1.7	1
34	Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram. American Health and Drug Benefits, 2011, 4, 78-87.	0.5	1
35	Assessing the economic impact of psychiatric disorders: where to begin?. Expert Opinion on Pharmacotherapy, 2001, 2, 641-652.	0.9	0
36	Cost of Illness: An Ongoing Battle Worth Fighting. Pharmacoeconomics, 2014, 32, 1151-1152.	1.7	0